
    
      A open label, randomized, crossover and potential parallel, single dose study of ticagrelor
      180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo
      platelet transfusion to determine the effects of platelet supplementation on the
      reversibility of platelet inhibition
    
  